Innovation in Biological Indicator Evaluator Resistometer Vessel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation in Biological Indicator Evaluator Resistometer Vessel Technology
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.


Pharmaceutical Technology



Table V: Fraction-negative D-values collected in triplicate on self-contained BI lot SC1 in three resistometers.
Fraction negative: self-contained BI. Fraction-negative data collected on the self-contained BI lot# SC1 are shown in Table V and Figure 11. Fraction-negative data collected on the self-contained BI lot SC2 are shown in Table VI and Figure 12. Fraction-negative data collected on the self-contained BI lot SC3 and SC4 are shown in Table VII.


Figure 11


Table VI: Fraction negative D-values collected in triplicate on self-contained BI lot SC2 in three resistometers.


Figure 12


Table VII. Fraction negative D-values collected on self-contained BI lots SC3 and SC4 in three resistometers.


Table VIII: Fraction negative D-values collected in triplicate on ampoule BI lot A1 in three resistometers.
Fraction negative: ampul BI. Fraction-negative data collected on the ampul BI lot A1 are shown in Table VIII and Figure 13.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here